4CPS-133 Is paracetamol a real alternative in the management of patent ductus arteriosus in preterm infants?

Background and importancePatent ductus arteriosus (PDA) is a common cause of morbidity and mortality in preterm infants. The treatment of choice is ibuprofen but contraindications and serious adverse events limits its use. Paracetamol has been proposed as an alternative to ibuprofen, with good resul...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A110-A111
Main Authors: Garcia Robles, AA, Iglesias Gómez, R, Pérez Huertas, P, Parra Llorca, A, Torres García, B, Gimeno Navarro, A, Vento Torres, M, Poveda Andrés, JL, Aguar Carrascosa, M
Format: Article
Language:English
Subjects:
Analgesics
Congenital diseases
Coronary vessels
Newborn babies
Nonsteroidal anti-inflammatory drugs
Premature babies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importancePatent ductus arteriosus (PDA) is a common cause of morbidity and mortality in preterm infants. The treatment of choice is ibuprofen but contraindications and serious adverse events limits its use. Paracetamol has been proposed as an alternative to ibuprofen, with good results (80–95% efficacy) and apparently less side effects.Aim and objectivesTo analyse the effectiveness and safety of intravenous paracetamol in the treatment of haemodynamically significant PDA (hsPDA).Material and methodsA retrospective cohort study of hospitalised infants was conducted in a level III neonatal intensive care unit between July 2013 and January 2019. Criteria inclusion: gestational age (GA) ≤30 weeks and treatment of hsPDA with paracetamol 15 mg/kg/6 hours (minimum 8 doses) after contraindication or ineffectiveness of ibuprofen. Closure was considered if the ductus was
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2020-eahpconf.234